The Ghent Marfan Trial--a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers.

[1]  A. Coats,et al.  Ethics in the authorship and publishing of scientific articles , 2010 .

[2]  Laurence Faivre,et al.  The revised Ghent nosology for the Marfan syndrome , 2010, Journal of Medical Genetics.

[3]  A. Zwinderman,et al.  Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial , 2010, Trials.

[4]  L. Tavazzi,et al.  Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations , 2009, Journal of cardiovascular medicine.

[5]  John Camm,et al.  Early impairment of left ventricular long-axis systolic function demonstrated by reduced atrioventricular plane displacement in patients with Marfan syndrome. , 2008, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[6]  A. Aggarwal,et al.  Effect of Perindopril on Large Artery Stiffness and Aortic Root Diameter in Patients With Marfan Syndrome A Randomized Controlled Trial , 2008 .

[7]  A. Fraser,et al.  Medical treatment of Marfan syndrome: a time for change , 2007, Heart.

[8]  S. Colan,et al.  Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. , 2007, American heart journal.

[9]  D. Judge,et al.  Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states , 2007, Nature Medicine.

[10]  L. Adès,et al.  Guidelines for the diagnosis and management of Marfan syndrome. , 2007, Heart, lung & circulation.

[11]  G. Jondeau,et al.  Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. , 2007, The American journal of cardiology.

[12]  Zhezhen Jin,et al.  The effect of beta-blocker therapy on clinical outcome in patients with Marfan's syndrome: a meta-analysis. , 2007, International journal of cardiology.

[13]  Patrick Segers,et al.  Primary impairment of left ventricular function in Marfan syndrome. , 2006, International journal of cardiology.

[14]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[15]  D. Judge,et al.  Marfan's syndrome , 2005, The Lancet.

[16]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[17]  P. Engelfriet,et al.  Aortic root growth in men and women with the Marfan's syndrome. , 2005, The American journal of cardiology.

[18]  B. McCrindle,et al.  Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. , 2005, The American journal of cardiology.

[19]  D. Judge,et al.  TGF-β–dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome , 2004 .

[20]  J. Ware,et al.  Applied Longitudinal Analysis , 2004 .

[21]  Pascal Verdonck,et al.  Functional analysis of the common carotid artery: relative distension differences over the vessel wall measured in vivo , 2004, Journal of hypertension.

[22]  D. Arking,et al.  Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome , 2003, Nature Genetics.

[23]  J. Dean.  Management of Marfan syndrome , 2002, Heart.

[24]  C. Nienaber,et al.  Therapeutic management of patients with Marfan syndrome: focus on cardiovascular involvement. , 1999, Cardiology in review.

[25]  P. Denes,et al.  Effect of long-term β-blockade on aortic root compliance in patients with Marfan syndrome , 1999 .

[26]  M. Roman,et al.  Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. , 1999, The American journal of cardiology.

[27]  J. Coselli,et al.  Replacement of the aortic root in patients with Marfan's syndrome. , 1999, The New England journal of medicine.

[28]  N. Kouchoukos,et al.  Life expectancy in the Marfan syndrome. , 1995, The American journal of cardiology.

[29]  R. Pyeritz,et al.  Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. , 1994, American Journal of Cardiology.

[30]  E. Murphy,et al.  Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. , 1994, The New England journal of medicine.

[31]  Ada Hamosh,et al.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene , 1991, Nature.

[32]  R. Devereux,et al.  Two-dimensional echocardiographic aortic root dimensions in normal children and adults. , 1989, The American journal of cardiology.

[33]  V. McKusick,et al.  Life expectancy and causes of death in the Marfan syndrome. , 1972, The New England journal of medicine.

[34]  J. Stockman,et al.  Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome , 2010 .

[35]  Marie-José Goumans,et al.  TGF-β signaling in vascular biology and dysfunction , 2009, Cell Research.

[36]  A. Braverman.  Transforming Growth Factor- (cid:1) A Biomarker in Marfan Syndrome? , 2022 .

[37]  M. Cheitlin.  Regression of Electrocardiographic Left Ventricular Hypertrophy During Antihypertensive Therapy and Reduction in Sudden Cardiac Death: The LIFE Study , 2008 .

[38]  Dionne A. Graham,et al.  Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. , 2007, The Journal of pediatrics.

[39]  D. Judge,et al.  TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. , 2004, The Journal of clinical investigation.

[40]  D. Arking,et al.  Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. , 2003, Nature genetics.

[41]  P. Denes,et al.  Effect of long-term beta-blockade on aortic root compliance in patients with Marfan syndrome. , 1999, American heart journal.

[42]  G. Maurer,et al.  Heterogeneous aortic response to acute beta-adrenergic blockade in Marfan syndrome. , 1997, American heart journal.

[43]  G. Maurer,et al.  Heterogeneous aortic response to acute β-adrenergic blockade in Marfan syndrome , 1997 .

[44]  R. Pyeritz,et al.  Marfan syndrome: current and future clinical and genetic management of cardiovascular manifestations. , 1993, Seminars in thoracic and cardiovascular surgery.

[45]  Transforming Growth Factor- (cid:1) A Biomarker in Marfan Syndrome? , 2022 .